I have long been convinced that there are nuggets of gold buried in the massive accumulation of 40 years of research that has built up since Ldopa took the stage. Common sense tells me that it is not possible for such a huge amount of data spread over several disciplines to build up without overlooking something invaluable. So, I look and I think that I have found something.It has made major improvements for me, at least, and continues to do so now, a month after starting it. There has been improvement across the board for me. Particularly impressive has been increased strength in my lower legs, greatly decreased OFF time, a decrease in medication, and a general increase in stamina.
This wonder drug was looked at in the late 1990s and found to increase dopamine in the striatum of the rat by 2.5 times. Most exciting, a small clinical trial tested its effect on seven human PD patients with very positive results.
And there the research stopped.
The drug is an ACE inhibitor called "perindopril" and it is extensively used for hypertension. Since I am already on similar medication, it was rather easy to convince my GP to indulge me. This is an "off label" use of a widely tested drug. I urge you to review the research and discuss with your own doctor a possible trial.
The following excerpts begin with the Pubmed ID Number to save space-
PMID:9048778 - Angiotensin-converting enzyme modulates dopamine turnover in the striatum.- "One week after perindopril treatment, striatal dopamine dialysate levels in the treated group were markedly elevated compared with control values: control, 233 +/- 43 pg/ml; perindopril, 635 +/- 53 pg/ml (p < 0.001)"
PMID: 10386973 - Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse.- "Our results demonstrate that perindopril is an effective agent in increasing striatal dopamine content in an animal model of Parkinson's disease."
PMID:10800878 - The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease.- "After a four week treatment period with perindopril, patients had a faster onset in their motor response to L-dopa and a reduction in 'on phase' peak dyskinesia, p=0.021 and p=0.014 respectively. Patients also reported more 'on' periods during their waking day in their movement diary, p=0.007. Perindopril was well tolerated without any significant postural hypotension or renal dysfunction."